Increased YKL-40 but Not C-Reactive Protein Levels in Patients with Alzheimer's Disease.
Victor Antonio Blanco-PalmeroMarcos Rubio-FernándezDesireé AntequeraAlberto Villarejo-GalendeJosé Antonio MolinaIsidro FerrerFernando BartoloméEva CarroPublished in: Biomedicines (2021)
Neuroinflammation is a common feature in Alzheimer's (AD) and Parkinson's (PD) disease. In the last few decades, a testable hypothesis was proposed that protein-unfolding events might occur due to neuroinflammatory cascades involving alterations in the crosstalk between glial cells and neurons. Here, we tried to clarify the pattern of two of the most promising biomarkers of neuroinflammation in cerebrospinal fluid (CSF) in AD and PD. This study included cognitively unimpaired elderly patients, patients with mild cognitive impairment, patients with AD dementia, and patients with PD. CSF samples were analyzed for YKL-40 and C-reactive protein (CRP). We found that CSF YKL-40 levels were significantly increased only in dementia stages of AD. Additionally, increased YKL-40 levels were found in the cerebral orbitofrontal cortex from AD patients in agreement with augmented astrogliosis. Our study confirms that these biomarkers of neuroinflammation are differently detected in CSF from AD and PD patients.
Keyphrases
- mild cognitive impairment
- cognitive decline
- end stage renal disease
- cerebrospinal fluid
- ejection fraction
- cognitive impairment
- newly diagnosed
- traumatic brain injury
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- spinal cord injury
- signaling pathway
- patient reported outcomes
- oxidative stress
- deep learning